Prediction of theophylline dosage regimens from limited serum sampling. 1982

J D Robinson, and P G Boysen, and S M Lupkiewicz, and J P Krischer, and M Ariet

Intravenous aminophylline was administered to 13 subjects (6 normal, 7 with chronic obstructive pulmonary disease), and multiple blood specimens were drawn over an 8-hour period for theophylline analysis. Half of the samples were obtained during the distribution phase of the drug and the remainder during the elimination phase. These data were entered into a computer program that both calculates and graphically displays individual two-compartment pharmacokinetic data, and recommends a dosing regimen. Analysis of these data demonstrates wide variability in the theophylline volume of distribution, half-life, and predicted dosage regimen. Dosage regimens can be individualized by obtaining two specimens for theophylline analysis during the elimination phase after intravenous administration of the drug; these regimens correlate extremely well (r2 = 0.95) with those designed using all the data points.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012984 Software Sequential operating programs and data which instruct the functioning of a digital computer. Computer Programs,Computer Software,Open Source Software,Software Engineering,Software Tools,Computer Applications Software,Computer Programs and Programming,Computer Software Applications,Application, Computer Software,Applications Software, Computer,Applications Softwares, Computer,Applications, Computer Software,Computer Applications Softwares,Computer Program,Computer Software Application,Engineering, Software,Open Source Softwares,Program, Computer,Programs, Computer,Software Application, Computer,Software Applications, Computer,Software Tool,Software, Computer,Software, Computer Applications,Software, Open Source,Softwares, Computer Applications,Softwares, Open Source,Source Software, Open,Source Softwares, Open,Tool, Software,Tools, Software
D013806 Theophylline A methyl xanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Theophylline inhibits the 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE that degrades CYCLIC AMP thus potentiates the actions of agents that act through ADENYLYL CYCLASES and cyclic AMP. 1,3-Dimethylxanthine,3,7-Dihydro-1,3-dimethyl-1H-purine-2,6-dione,Accurbron,Aerobin,Aerolate,Afonilum Retard,Aquaphyllin,Armophylline,Bronchoparat,Bronkodyl,Constant-T,Elixophyllin,Euphylong,Glycine Theophyllinate,Lodrane,Monospan,Nuelin,Nuelin S.A.,Quibron T-SR,Slo-Phyllin,Somophyllin-T,Sustaire,Synophylate,Theo Von Ct,Theo-24,Theo-Dur,Theobid,Theocin,Theoconfin Continuous,Theodur,Theolair,Theolix,Theon,Theonite,Theopek,Theophylline Anhydrous,Theophylline Sodium Glycinate,Theospan,Theostat,Theovent,Uniphyl,Uniphyllin,Uniphylline,1,3 Dimethylxanthine,Anhydrous, Theophylline,Constant T,ConstantT,Ct, Theo Von,Glycinate, Theophylline Sodium,Quibron T SR,Quibron TSR,Slo Phyllin,SloPhyllin,Sodium Glycinate, Theophylline,Somophyllin T,SomophyllinT,Theo 24,Theo Dur,Theo24,Theophyllinate, Glycine,Von Ct, Theo
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

J D Robinson, and P G Boysen, and S M Lupkiewicz, and J P Krischer, and M Ariet
January 1988, Therapeutic drug monitoring,
J D Robinson, and P G Boysen, and S M Lupkiewicz, and J P Krischer, and M Ariet
June 1979, American journal of hospital pharmacy,
J D Robinson, and P G Boysen, and S M Lupkiewicz, and J P Krischer, and M Ariet
September 1985, Journal of veterinary pharmacology and therapeutics,
J D Robinson, and P G Boysen, and S M Lupkiewicz, and J P Krischer, and M Ariet
January 1979, American journal of hospital pharmacy,
J D Robinson, and P G Boysen, and S M Lupkiewicz, and J P Krischer, and M Ariet
February 1984, Annals of emergency medicine,
J D Robinson, and P G Boysen, and S M Lupkiewicz, and J P Krischer, and M Ariet
December 1982, International journal of clinical pharmacology, therapy, and toxicology,
J D Robinson, and P G Boysen, and S M Lupkiewicz, and J P Krischer, and M Ariet
July 1989, Journal of clinical pharmacology,
J D Robinson, and P G Boysen, and S M Lupkiewicz, and J P Krischer, and M Ariet
September 1982, Pediatrics,
J D Robinson, and P G Boysen, and S M Lupkiewicz, and J P Krischer, and M Ariet
May 1976, JAMA,
J D Robinson, and P G Boysen, and S M Lupkiewicz, and J P Krischer, and M Ariet
April 2024, Therapeutic drug monitoring,
Copied contents to your clipboard!